Study Results

Results from the study’s primary objectives include:

In adults 50 years of age and older (Cohort 1), V116 elicited non-inferior immune responses compared to PCV20 for all ten serotypes common to both vaccines as measured by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) at Day 30.

Immune responses elicited by V116 were superior for 10 of 11 serotypes included in V116 but not in PCV20 as measured by OPA GMTs at Day 30, and the proportions of patients with a greater than or equal to four-fold increase in OPA from Day 1 to Day 30.

In adults 18 to 49 (Cohort 2), V116 elicited non-inferior immune responses (immunobridged) compared to adults 50 to 64, as assessed by serotype-specific OPA GMTs 30 days post-vaccination.

Across both cohorts, V116 had a safety profile comparable to PCV20.